Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22121865 | 0.92 | CHRM4 (0.32) | CHRM4 | |
| SCHEMBL16441790 | 0.84 | CHRM4 (0.33) | CHRM4EPHX2 | |
| SCHEMBL16441723 | 0.79 | CHRM4 (0.36) | CHRM4 | |
| SCHEMBL17168910 | 0.79 | PIK3CA (0.32) | CHRM4 | |
| SCHEMBL20085792 | 0.75 | ADORA2A (0.36) | — | |
| SCHEMBL16441737 | 0.75 | CHRM4 (0.33) | CHRM4 | |
| SCHEMBL10899348 | 0.75 | ACACB (0.31) | — | |
| SCHEMBL25464078 | 0.75 | CHRM4 (0.31) | CHRM4 | |
| SCHEMBL16441705 | 0.75 | PDPK1 (0.33) | CHRM4 | |
| SCHEMBL31155924 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115850189-A | Method for continuous flow synthesis of 5-bromo-6-cyclopropylpyrimidine-4-ol | 武汉海特生物创新医药研究有限公司 | 2023-03-28 | — | — | CN | claimed |
| US-20250163049-A1 | FUSED BICYCLIC HETEROCYCLYL COMPOUNDS AS USP1 INHIBITORS | EXELIXIS INC (US) | 2025-05-22 | — | — | US | disclosed |
| WO-2025096539-A1 | UBIQUITIN SPECIFIC PROCESSING PROTEASE 1 (USP1) COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-05-08 | — | — | WO | disclosed |
| US-20250145590-A1 | UBIQUITIN SPECIFIC PROCESSING PROTEASE 1 (USP1) COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-05-08 | — | — | US | disclosed |
| EP-4547336-A1 | USP1 INHIBITORS AND USES THEREOF | Zentaur Therapeutics USA Inc. (US) | 2025-05-07 | — | — | EP | disclosed |
| CN-119836421-A | USP1 inhibitors and uses thereof | 森韬医药美国公司 | 2025-04-15 | — | — | CN | disclosed |
| US-20250034133-A1 | SMALL MOLECULE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 1 (USP1) AND USES THEREOF | INSILICO MEDICINE IP LIMITED (HK) | 2025-01-30 | — | — | US | disclosed |
| CN-119173512-A | Small molecule inhibitors of ubiquitin-specific protease 1 (USP 1) and uses thereof | 英矽智能科技知识产权有限公司 | 2024-12-20 | — | — | CN | disclosed |
| EP-4472946-A1 | FUSED BICYCLIC HETEROCYCLYL COMPOUNDS AS USP1 INHIBITORS | Exelixis, Inc. (US) | 2024-12-11 | — | — | EP | disclosed |
| EP-4430041-A1 | SMALL MOLECULE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 1 (USP1) AND USES THEREOF | Insilico Medicine IP Limited (HK) | 2024-09-18 | — | — | EP | disclosed |
| CN-115850189-A | Method for continuous flow synthesis of 5-bromo-6-cyclopropylpyrimidine-4-ol | 武汉海特生物创新医药研究有限公司 | 2023-03-28 | — | — | CN | disclosed |
| CN-115850189-A | Method for continuous flow synthesis of 5-bromo-6-cyclopropylpyrimidine-4-ol | 武汉海特生物创新医药研究有限公司 | 2023-03-28 | — | — | CN | disclosed |
| WO-2022228399-A1 | TRICYCLIC USP1 INHIBITOR AND USE THEREOF | 山东轩竹医药科技有限公司 | 2022-11-03 | — | — | WO | disclosed |
| US-11485736-B2 | Substituted pyrazolopyrimidines and substituted purines and their use as ubiquitin-specific-processing protease 1 (USP1) inhibitors | KSQ Therapeutics, Inc. (US) | 2022-11-01 | — | — | US | disclosed |
| WO-2022106547-A1 | PROCESS FOR SYNTHESISING A ROR GAMMA INHIBITOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-05-27 | — | — | WO | disclosed |
| EP-3897652-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES AND SUBSTITUTED PURINES AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS | KSQ Therapeutics, Inc. (US) | 2021-10-27 | — | — | EP | disclosed |
| CN-113164485-A | Substituted pyrazolopyrimidines and substituted purines and their use as inhibitors of ubiquitin-specific processing protease 1(USP1) | KSQ治疗公司 | 2021-07-23 | — | — | CN | disclosed |
| US-20210115049-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES AND SUBSTITUTED PURINES AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS | KSQ Therapeutics, Inc. | 2021-04-22 | — | — | US | disclosed |
| WO-2020132269-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES AND SUBSTITUTED PURINES AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS | KSQ Therapeutics, Inc. (US) | 2020-06-25 | — | — | WO | disclosed |
| WO-2000063176-A2 | DISUBSTITUTED PYRIDINES AND PYRIMIDINES AS HERBICIDES AND FUNGICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 2000-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210115049-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES AND SUBSTITUTED PURINES AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS | USP1, UPP1, USP2 | CHRM4 3448/4885EPHX2 3593/4885 |
| US-11485736-B2 | Substituted pyrazolopyrimidines and substituted purines and their use as ubiquitin-specific-processing protease 1 (USP1) inhibitors | USP1, UPP1, USP2 | CHRM4 3448/4885EPHX2 3593/4885 |
| US-20250034133-A1 | SMALL MOLECULE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 1 (USP1) AND USES THEREOF | USP1, USP2, USP28 | CHRM4 4837/4885EPHX2 3790/4885 |
| US-20250145590-A1 | UBIQUITIN SPECIFIC PROCESSING PROTEASE 1 (USP1) COMPOUNDS | USP1, UBA1, SUMO1 | CHRM4 4787/4885EPHX2 4474/4885 |
| US-20250163049-A1 | FUSED BICYCLIC HETEROCYCLYL COMPOUNDS AS USP1 INHIBITORS | USP1, USP2, SUMO1 | CHRM4 4831/4885EPHX2 3654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.